Roivant Sciences Ltd.

ROIV Healthcare Biotechnology

Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.

Revenue
−33.6%
EPS
+21.2%
Free cash flow
−30.0%

Quarter to June 2026, against a year earlier

38.90 2.28 +6.23%
Market cap
$26.5B
P/E
0.0×
Fwd P/E
−27.7×
Dividend yield
—
F-score
2/9
Altman Z
28.31
Beneish M
n/a
Dividend safety
n/a

Roivant Sciences Ltd. (ROIV) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, Roivant Sciences Ltd. (ROIV) trades at a EV/FCF of −28.1×. Over the past ten years it has ranged from −32.4× (September 2026) to 0.0× (March 2021); the current reading is higher than 1% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2026 −20.4× —
FY2025 −3.3× —
FY2024 −2.8× —
FY2023 −4.7× —
FY2022 −2.1× —
FY2021 −7.5× —

Quarterly newest first

Period EV/FCF Change
Jun 2026 −26.8× —
Mar 2026 −20.4× —
Dec 2025 −14.2× —
Sep 2025 −8.0× —
21 more quarters

Against its own ten years

Low −32.4× High 0.0×
Ten-year median −4.8×
Current reading's percentile 1

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on ROIV